Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis

Cheung, Dianne S; Bryer‐Ash, Michael

doi:10.1016/j.jaad.2008.12.012

Cited by 15 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been multiple case reports of hypoglycemia associated with etanercept, an anti-TNF treatment, in patients with psoriasis and type 2 DM 67–69. TNF-mediated inflammation has been shown to mediate insulin resistance 70.…”

Section: Cardiovascular Disease and Risk Factorsmentioning

confidence: 99%

Psoriasis and comorbidities: links and risks

Ni¹,

Chiu²

2014

CCID

View full text Add to dashboard Cite

Psoriasis is a chronic inflammatory skin disease affecting approximately 2% of the population worldwide. In the past decade, many studies have drawn attention to comorbid conditions in psoriasis. This literature review examines the epidemiological evidence, pathophysiological commonalities, and therapeutic implications for different comorbidities of psoriasis. Cardiovascular disease, obesity, diabetes, hypertension, dyslipidemia, metabolic syndrome, nonalcoholic fatty liver disease, cancer, anxiety and depression, and inflammatory bowel disease have been found at a higher prevalence in psoriasis patients compared to the general population. Because of the wide range of comorbid conditions associated with psoriasis, comprehensive screening and treatment must be implemented to most effectively manage psoriasis patients.

show abstract

Section: Cardiovascular Disease and Risk Factorsmentioning

confidence: 99%

Psoriasis and comorbidities: links and risks

Ni¹,

Chiu²

2014

CCID

View full text Add to dashboard Cite

show abstract

“…No clear effects on insulin sensitivity or beta cell function were observed after administration of recombinant TNF-α inhibitors despite a decrease in systemic levels of proinflammatory immune mediators [87], except for some cases of concomitant hypoglycaemia [88]. The doses of inhibitors administered were effective in rheumatoid arthritis but whether they were sufficient to suppress the paracrine effects of IL-1 or TNF-α in fat or muscle tissue is not known.…”

Section: Lessons From Immune Intervention Trialsmentioning

confidence: 99%

The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation

Kolb¹,

2009

View full text Add to dashboard Cite

The recent major increase in the global incidence of type 2 diabetes suggests that most cases of this disease are caused by changes in environment and lifestyle. All major risk factors for type 2 diabetes (overnutrition, low dietary fibre, sedentary lifestyle, sleep deprivation and depression) have been found to induce local or systemic low-grade inflammation that is usually transient or milder in individuals not at risk for type 2 diabetes. By contrast, inflammatory responses to lifestyle factors are more pronounced and prolonged in individuals at risk of type 2 diabetes and appear to occur also in the pancreatic islets. Chronic low-grade inflammation will eventually lead to overt diabetes if counter-regulatory circuits to inflammation and metabolic stress are compromised because of a genetic and/or epigenetic predisposition. Hence, it is not the lifestyle change per se but a deficient counter-regulatory response in predisposed individuals which is crucial to disease pathogenesis. Novel approaches of intervention may target these deficient defence mechanisms.

show abstract

“…Several episodes of hypoglycaemia after the initiation of anti-TNF-alpha therapy have been reported in two women with rheumatoid arthritis, one also affected by type 2 diabetes [20] and the other by latent autoimmune diabetes of adults (LADA) [21], for which it was necessary to reduce, in both of them, the doses of exogenous insulin [20,21]. In an elderly man suffering from type 2 diabetes and psoriasis treated with etanercept, insulin was gradually reduced and finally replaced with rosiglitazone and repaglinide for frequent episodes of hypoglycaemia occurred [22]. The case of a woman suffering from JIA who developed T1DM during treatment with etanercept has been also described.…”

Section: Discussionmentioning

confidence: 99%

Refractory rheumatoid factor positive polyarthritis in a female adolescent already suffering from type 1 diabetes mellitus and Hashimoto’s thyroiditis successfully treated with etanercept

et al. 2013

View full text Add to dashboard Cite

Type 1 diabetes mellitus may be associated with many autoimmune diseases with the common autoimmune pathogenesis. We describe the case of a girl suffering from Type 1 diabetes mellitus and autoimmune Hashimoto's thyroiditis since the childhood and, due to the onset of Juvenile Idiopathic Arthritis during adolescence, for three years practiced therapy with an anti-TNF drug, etanercept . Currently her inflammatory markers are normal, arthritis is inactive and diabetes is well controlled. During the treatment with anti-TNF drug we observed a significative reduction of insulin dose, probably due to an increased tissue sensitivity secondary to the suppression of the activity of TNF-alpha. Several clinical trials that have evaluated the effect of immunomodulatory agents in diabetic patients, especially in those with recent onset of disease, were already performed but further studies of longer duration on a larger population are needed to assess the role of biologic drugs and immunotherapy in this group of patients.

show abstract

Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis

Cited by 15 publications

References 22 publications

Psoriasis and comorbidities: links and risks

Psoriasis and comorbidities: links and risks

The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation

Refractory rheumatoid factor positive polyarthritis in a female adolescent already suffering from type 1 diabetes mellitus and Hashimoto’s thyroiditis successfully treated with etanercept

Contact Info

Product

Resources

About